Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Hematopoietic stem cell transplantation

Allogeneic hematopoietic stem cell transplantation (HSCT) is the only potential cure for SCD. The best candidates are children with SCD who are younger than 16 years of age with severe complications who have an identical H LA-matched donor, usually a sibling. The transplant-related mortality rate is between 5% and 10%, and graft rejection is approximately 10%. Other risks include secondary malignancies, development of seizures or intracranial bleeding, and infection in the immediate posttransplant period.6,25,32,33... [Pg.1014]

Varicella VAR 0.5 mL Subcutaneous Allergic reaction to gelatin or neomycin Pregnant women Immunocompromised host Recently received a blood transfusion Hematopoietic stem cell transplant... [Pg.1242]

Following hematopoietic stem cell transplantation the patient will need virtually all routine vaccines to be administered again however, the patient will not be able to mount an adequate response for 6 to 12 months post-transplant. Diphtheria, tetanus, acellular pertussis, Haemophilus influenzae type b, hepatitis B, pneumococcal, and inactivated poliovirus should be given at 12,14, and 24 months post-hematopoietic stem cell transplantation. Inactivated influenza vaccine should be given yearly, starting 6 months after transplant. Measles, mumps and rubella can be given 2 years after transplant and varicella vaccine is contraindicated.16... [Pg.1249]

Assess the role of autologous hematopoietic stem cell transplantation in relapsed Hodgkin s lymphoma and non-Hodgkin s lymphoma. [Pg.1371]

Allogeneic hematopoietic stem cell transplantation (HSCT) has been used in the treatment of pediatric AML in first complete remission. In most clinical trials, the availability of HLA-matched sibling donors determined whether patients underwent HSCT as postremission treatment. To facilitate this process, it is important to obtain HLA typing on all younger patients with AML and siblings shortly after diagnosis. Patients who do not have an HLA-matched sibling will proceed to postremission therapy. [Pg.1410]

Baron F, Sandmaier BM. Current status of hematopoietic stem cell transplantation after nonmyeloablative conditioning. Curr Opin Hematol 2005 12 435 43. [Pg.1465]

Copelan EA. Hematopoietic stem-cell transplantation. New Engl J Med 2006 354 1813-1826. [Pg.1465]

Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 2000 49 1-125, CE1-7. [Pg.1465]

Leather HL. Drug interactions in the hematopoietic stem cell transplant (HSCT) recipient What every transplanter needs to know. Bone Marrow Transplant 2004 33 137-152. [Pg.1465]

Hematopoietic Stem Cell Transplantation/Leukemia Shands... [Pg.1701]

Hematopoietic stem cell transplants as treatment for glial disease 513... [Pg.503]

Allogeneic hematopoietic stem cell transplantation is the only therapy that is curative. The best candidates are younger than 16 years of age, have severe complications, and have human leukocyte antigen-matched donors. Risks must be carefully considered and include mortality, graft rejection, and secondary malignancies. [Pg.386]

EN, enteral nutrition HSCT, hematopoietic stem cell transplantation PN, parenteral nutrition. [Pg.683]

Salvage chemotherapy at conventional doses or high-dose chemotherapy and autologous hematopoietic stem cell transplantation... [Pg.718]

Patients who relapse after an initial complete response can be treated with the same regimen, a non-cross-resistant regimen, radiation therapy, or high-dose chemotherapy and autologous hematopoietic stem cell transplantation (HSCT). [Pg.719]

Burt R, Traynor A, Statkute L, et al Non-myeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA 2006 295 527-535. [Pg.218]

Snowden J, Passweg J, Moore J, et al Autologous hematopoietic stem cell transplantation in severe rheumatoid arthritis a report from the EBMT and ABMTR. J Rheumatol 2004 31 482-488. [Pg.218]

Ades L, Guardiola P, Socle G Second 12 malignancies after allogeneic hematopoietic stem cell transplantation new insight and current problems. Blood Rev 2002 16 135-146. [Pg.219]

Autologous non-myeloablative hematopoietic stem cell transplantation in patients with systemic sclerosis. Bone Marrow Transplant 2007 40 549-555. [Pg.219]

Voltarelli J, Couri C, Stracieri A, et al Autologous nonmyeloablative hematopoietic stem cell transplantation 15 in newly diagnosed type 1 diabetes mellitus. JAMA 2007 297 1568-1576. [Pg.219]

Gratwohl A, Baldomero H, Schmid 0 et al. Change in stem cell source for hematopoietic stem cell transplantation (HSCT) in Europe a report of the EBMT activity survey 2003. Bone Marrow Transplant. 2005 36 575-590. [Pg.60]

Gluckman E. (2000) Current status of umbilical cord blood hematopoietic stem cell transplantation, Exp HeinatolZS, 1197-1205. [Pg.209]

Up until the 1970s, CML was incurable. The development of allogeneic hematopoietic stem cell transplantation (HSCT) was subsequently shown to provide long-term disease eradication with prolonged disease-free survival (14). However, allogeneic HSCT is available to only a minority of patients because of the necessity of finding a suitable donor for transplantation and the toxicity of the procedure. [Pg.132]

Rituximab Induced Neutropenia After Autologous Hematopoietic Stem Cell Transplantation for Lymphoma... [Pg.223]

See other pages where Hematopoietic stem cell transplantation is mentioned: [Pg.291]    [Pg.1004]    [Pg.1014]    [Pg.1018]    [Pg.1226]    [Pg.1298]    [Pg.1410]    [Pg.1410]    [Pg.1413]    [Pg.1456]    [Pg.505]    [Pg.513]    [Pg.516]    [Pg.35]    [Pg.39]    [Pg.124]    [Pg.211]    [Pg.202]    [Pg.203]    [Pg.264]    [Pg.33]    [Pg.1696]    [Pg.745]   
See also in sourсe #XX -- [ Pg.39 , Pg.40 ]

See also in sourсe #XX -- [ Pg.116 , Pg.338 , Pg.339 ]



SEARCH



Cell transplantation

Hematopoietic

Hematopoietic cells

Hematopoietic stem cell transplants

© 2024 chempedia.info